

Statements of Financial Position

As of December 31	2013	2012
Assets		
Cash and equivalents	\$ 18,432,179	\$ 8,359,719
Dividend receivable	66,478,694	66,478,694
Other receivables	31,975,423	32,121,269
Investments — at fair value:		
United States government and agency, bank, and corporate interest-bearing obligations	49,938,712	82,691,271
Eli Lilly and Company common stock (cost — \$84,798,379 at December 31, 2013 and 2012)	6,919,211,004	6,691,284,053
Diversified equity investments	613,022,235	476,471,345
Other assets	152,869	219,596
	\$ 7,699,211,116	\$ 7,357,625,947
Liabilities		
Amounts appropriated for future grants	\$ 8,849,750	\$ 20,728,500
Deferred tax liability	132,113,781	125,067,113
	140,963,531	145,795,613
Unrestricted net assets	7,558,247,585	7,211,830,334
	\$ 7,699,211,116	\$ 7,357,625,947

See accompanying notes.

Statements of Activities and Changes in Unrestricted Net Assets

Year ended December 31	2013	2012
Income:		
Dividends	\$ 278,065,418	\$ 277,372,909
Interest	219,125	285,550
Total income	278,284,543	277,658,459
Deductions:		
Grants approved	265,259,072	246,185,616
Expenses:		
Program support	6,194,058	6,371,294
Operational support	5,780,931	7,787,573
Federal excise tax	12,593,799	28,078,020
Total grants approved and expenses	289,827,860	288,422,503
Gain on sale of investment	—	309,306
Increase in unrealized appreciation of marketable securities	352,208,280	1,106,838,087
Other income	5,752,288	1,443,053
Increase in unrestricted net assets	346,417,251	1,097,826,402
Unrestricted net assets:		
Balance at beginning of year	7,211,830,334	6,114,003,932
Increase in unrestricted net assets	346,417,251	1,097,826,402
Balance at end of year	\$ 7,558,247,585	\$ 7,211,830,334

See accompanying notes.

Statements of Cash Flows

Year ended December 31	2013	2012
Operating activities		
Increase in unrestricted net assets	\$ 346,417,251	\$ 1,097,826,402
Adjustments to reconcile increase in unrestricted net assets to net cash (used in) provided by operating activities:		
Investment expenses	257,055	246,398
Gain on mark-to-market adjustments on investments	(352,208,280)	(1,106,838,087)
Gain on sale of investment	—	(309,306)
Changes in assets and liabilities:		
Dividend and other receivables	145,846	4,495,053
Other assets	66,727	(21,039)
Amount appropriated for future grants	(11,878,750)	12,036,669
Deferred federal excise tax liability	7,046,668	22,133,513
Net cash (used in) provided by operating activities	(10,153,483)	29,569,603
Investing activities		
Purchases of investments	(192,787,279)	(324,109,009)
Proceeds from sale and maturity of investments	213,270,277	291,580,922
Investment expenses	(257,055)	(246,398)
Net cash provided by (used in) investing activities	20,225,943	(32,774,485)
Net increase (decrease) in cash	10,072,460	(3,204,882)
Cash and equivalents at beginning of year	8,359,719	11,564,601
Cash and equivalents at end of year	\$ 18,432,179	\$ 8,359,719

See accompanying notes.